Lean African Patients With Type 2 Diabetes Have Distinct Disease Process

Differing Disease Mechanisms Across Patient Demographics

Type 2 diabetes is widely characterized as a condition tied directly to excess body weight, a pattern that holds true in wealthy nations where roughly nine out of ten patients are overweight, according to the Amsterdam UMC findings. In Africa, however, the clinical picture diverges significantly. Project data reveals that nearly four out of ten African adults with type 2 diabetes maintain a normal or low body weight. In rural settings like Ghana, that figure increases to six out of ten individuals.

This means that there are an estimated ten million lean patients on the African continent who do not fit the standard picture, said Sabrina Esmail, first author of the study at Amsterdam UMC, in published statements. At their core, the problem is a shortage of insulin, not a reduced response to insulin.

Treatment Mismatches and Clinical Complications

Despite the underlying biological differences, standard international treatment guidelines prescribe the same therapies for both groups. Patients across Africa frequently receive oral tablets such as metformin or sulfonylureas. Investigators note that these specific medications work effectively against insulin resistance rather than addressing an outright deficiency in insulin production. Consequently, lean patients likely receive therapies unsuited to their specific disease subtype.

To reach these conclusions, researchers examined data covering more than 3,300 African adults diagnosed with type 2 diabetes across Ghana, Nigeria, Kenya, and Europe. The analysis highlighted distinct complication patterns between cohorts. According to senior author Felix Chilunga, lean patients develop eye damage, known as retinopathy, and strokes at higher rates, whereas heavier individuals face an increased incidence of high blood pressure and cardiovascular disease. Chronic kidney disease appeared with equal frequency across both groups.

Implications for African Patient Populations in Europe

The treatment mismatch extends beyond the African continent. Separate findings utilizing data from the UK Biobank indicate that individuals of African descent with a body mass index of 26 face a diabetes risk equivalent to that of European populations with a body mass index of 30. Migration studies consistently show that people of African heritage develop type 2 diabetes more frequently, manifest the condition roughly ten years earlier, and exhibit poorer blood sugar control than native European populations.

So a significant proportion of African patients in Europe are lean, are treated according to guidelines written for the form of the disease in overweight people, and their control is demonstrably poorer, stated Charles Agyemang, project leader at Amsterdam UMC. There is no reason to assume that the treatment mismatch we describe stops at the border.

The research collaboration involved Amsterdam UMC, the University of Ghana, and the National Institutes of Health, specifically operating through the Center for Research on Genomics and Global Health via the AADM and RODAM cohorts. Investigators emphasize the urgent need for tailored clinical trials to establish optimized treatment protocols for this substantial and frequently overlooked patient population.